S. Ramanathan

A multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons

F. Henskens, R. Sanson-Fisher, C. Oldmeadow, 2019, Journal of psychosocial oncology.

The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation

S. Ramanathan, A. Trickett, Y. Kwan, 2012, Annals of Hematology.

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).

B. Chong, S. Ramanathan, F. Roncolato, 2015, Blood.

‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma

S. Ramanathan, C. Tiley, S. Harrison, 2018, Leukemia & lymphoma.

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma

Peter Shaw, S. Ramanathan, C. Tiley, 2022, European Journal of Clinical Pharmacology.

7 + 3 idarubicin is still an effective induction therapy in acute myeloid leukaemia

S. Ramanathan, X. Badoux, M. Rezo, 2014, Internal medicine journal.

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

M. Casey, J. Boni, S. Ramanathan, 2018, Leukemia & lymphoma.

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

P. Marlton, A. Roberts, A. Wei, 2023, Blood.